{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017015","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.630065+00:00","generated_at":"2026-06-22T01:56:57.041557+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xilio Therapeutics Q3 2022 net loss $19.8M; XTX202 reaches target dose; XTX301 IND cleared","bullets":["Cash $139.1M as of Sep 30, 2022; runway into Q2 2024.","Net loss $19.8M in Q3 2022 vs $16.3M in Q3 2021; R&D expense $13.0M.","XTX202 (IL-2) dosed at target 1 mg/kg; no vascular leak syndrome; CD8+ T cell increases seen.","FDA cleared IND for XTX301 (IL-12); Phase 1 start expected Q1 2023.","Company will seek partner for XTX101 (anti-CTLA-4); will not initiate a Phase 2 alone."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017015","json":"https://secwatch.observer/filing/0001558370-22-017015.json","markdown":"https://secwatch.observer/filing/0001558370-22-017015.md","text":"https://secwatch.observer/filing/0001558370-22-017015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/0001558370-22-017015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/xlo-20221109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:56:57.041557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"095a68e1bada6f2390771b271e53468e71201fcd","claim":"Xilio Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/0001558370-22-017015-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}